About: Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Thing, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
value	Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study
Subject	Sanofi Food and Drug Administration Clinical trials Drug discovery Clinical research Clinical pharmacology Design of experiments Medical statistics Pharmaceutical industry RTT World Health Organization essential medicines Platinum-based antineoplastic agents
part of	Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study
is hasSource of	covid:ann/target/e7078f0ba297ff58f62e6a470c79908474a719fc covid:ann/target/75e2b89ad024701cd85287bb2145ad36d6c1a6e3 covid:ann/target/02aa045904695b1096c30c40da5631c5d3f1c022 covid:ann/target/cec8a70eeecb75703b8e411a563ef691496f0ba7 covid:ann/target/6cf41cacd126dbb50abd68688ab514a5df3b5f50 covid:ann/target/3e9be457e710e9d3ce378de18b5b30d80470d9c5 covid:ann/target/64dd8cff0839f4b16c3e2533f57d4cc433138be3 covid:ann/target/431b166a22e49a29c3dac45f4c6f417479887213 covid:ann/target/86d1f9d9e5097e6c5401a836f2442e7d700ebe2d covid:ann/target/d1c873e5b7791e7b468d757c165bf47773572978 covid:ann/target/0cb0d608364dd2a1b3a8037da84dd0f8aa9bb129 covid:ann/target/724f6bfc05289b3405ff44d039b85ea8eb00b24f covid:ann/target/a3287bcf48a23456f8306e238433d056cc77e0a6 covid:ann/target/da8b3a5c8d4b68937955dbafc3ca5c7bb22902d5 covid:ann/target/0d6915e3e4767aaac5e606ace42cfe4ad3388caa covid:ann/target/ae70d77e0e23173a7924a264ba471a7aa84f8856 covid:ann/target/cc05cade33fc338975e84bf75993713e8826ec72 covid:ann/target/ef0dda3c71c840a5c0f69f282925c4ee99a68c83 covid:ann/target/ca0d31d06ba6c574c90f994985d5b21ef5dc9d95 covid:ann/target/e87a60b7adb740e8479e436a92cd45fbb0851c91 covid:ann/target/2e81ebab79cc031abcd1dc3be93e6545bdaaddcd covid:ann/target/5cf0c87e64a46dcf62e2fd0e336f4345abe46871 covid:ann/target/e38292b93705ea767358c5fecbd002e78ad87426 covid:ann/target/397fdadc2f85a5e0e8028eb7f17a2cd308a8857c covid:ann/target/8c1366c612dade3f803af3f3c3a54657bfcd2b4a covid:ann/target/a40ce72d8420fe2a4e9a1e18f987045c6a996974
is resource representing a document's title of	Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software